- A daily pill with low doses of telmisartan, amlodipine, and indapamide, known as ‘GMRx2,’ lowers blood pressure more effectively than standard treatments.
- Participants on ‘GMRx2’ experienced a 31 mm Hg reduction in systolic blood pressure compared to 26 mm Hg with standard care.
- The study, published in JAMA and presented at the European Society of Cardiology Congress 2024, highlights the pill’s significant impact on blood pressure control.
A recent study published in the Journal of the American Medical Association (JAMA) reveals that a single daily pill containing low doses of telmisartan, amlodipine, and indapamide—referred to as ‘GMRx2’—is more effective at managing hypertension than traditional treatments.
This combination pill was shown to reduce systolic blood pressure by 31 mm Hg, compared to a 26 mm Hg reduction with standard care, over a six-month period.
Combination Pill with Three Drugs Outperforms Standard Hypertension Treatments
The ‘GMRx2’ treatment plan was presented at the European Society of Cardiology Congress 2024 and is based on a novel approach of combining low doses of these three anti-hypertensive drugs. After just one month, a significant 81% of participants on the ‘GMRx2’ regimen achieved controlled blood pressure, surpassing the 55% success rate of those receiving standard care.
The research, led by The George Institute for Global Health and recently presented at the European Society of Cardiology Congress 2024, revealed that participants on the ‘GMRx2’ regimen experienced a 31 mm Hg reduction in systolic blood pressure, significantly greater than the 26 mm Hg reduction observed with traditional treatments. This difference, amounting to 5.8 mm Hg, has been deemed both clinically and statistically significant.
In addition to its superior blood pressure-lowering effects, the ‘GMRx2’ pill also demonstrated faster results. Within just one month, 81% of patients taking the ‘GMRx2’ pill achieved controlled blood pressure, compared to only 55% of those receiving standard care. This early success highlights the pill’s potential for improving hypertension management.
Professor Dike Ojji, head of the cardiovascular research unit at the University of Abuja, emphasized that the ‘GMRx2’ pill’s effectiveness in reducing blood pressure underscores its promise as a significant advancement in hypertension treatment. This novel approach could revolutionize how hypertension is managed globally, particularly in low- and middle-income countries where hypertension is prevalent.
The ‘GMRx2’ combination pill represents a promising advancement in hypertension treatment, demonstrating superior efficacy and faster results compared to traditional therapies. Its potential to significantly impact blood pressure management offers hope for improved health outcomes, particularly for individuals in regions with high hypertension rates.
“The triple pill still produced clinically meaningful reductions in blood pressure compared to standard care,
